Time To Revamp Your Online Privacy Disclosures

On March 19, 2015, the United States District Court in the District of Minnesota gave preliminary approval to a proposed settlement for the December 2013 data breach suffered by Target Corporation.

Federal and provincial privacy regulators have concluded a multi-year investigation into OpenAI's data practices, finding contraventions of Canadian privacy legislation in how personal information was collected and used...

Canada's privacy regulator has released new draft guidance establishing comprehensive due diligence standards for organizations evaluating third-party service providers under PIPEDA. The framework introduces eleven best practices covering everything from data flow mapping and AI training data sourcing to vendor lock-in risks and ongoing monitoring obligations, signaling heightened expectations for privacy accountability in vendor relationships.

Since Canada's anti-spam legislation (CASL) was enacted in 2014, businesses have been faced with the challenge of keeping adequate records of their authority to send commercial electronic messages under CASL's various categories of express and implied consent.

The Canadian market is ripe with opportunities for U.S. companies seeking to expand beyond domestic borders. Before diving in, however, it can be helpful to have a basic understanding of Canada's legal system...

Canada's federal government has introduced Bill C-36, marking a significant departure from its predecessor Bill C-27 by unbundling AI regulation from privacy reform and establishing a new regulatory framework centered...

These regulations, which include fines of up to $100,000CAD for non-compliance, will come into force on November 1, 2018.

The Ontario government recently amended the Personal Health Information Protection Act (PHIPA) to include mandatory breach reporting.

Canada's proposed Bill C-36 would fundamentally transform private-sector privacy law by replacing PIPEDA with the Protecting Privacy and Consumer Data Act. Organizations face stricter data collection tests, new consent exceptions, explicit AI governance rules, and penalties reaching $25 million or 5% of global revenue for knowing violations.

Canada's proposed Bill C-36 introduces sweeping reforms to private sector privacy law, replacing PIPEDA with the Protecting Privacy and Consumer Data Act.

Health Canada issued revised guidance on notifying Health Canada of foreign actions, effective October 1, 2026. The revised guidance clarifies the requirements to notify Health Canada of certain foreign regulatory actions specified in subsection C.01.050(2) of the Food and Drug Regulations in the specified foreign jurisdictions, which involve a serious risk of injury to human health and are relevant to the safety of the drug.

COLD-FX is a top-selling natural health product in Canada, with sales topping nearly $120-million as recently as 2011, according to a November 15, 2015 Globe and Mail article, "Why COLD-FX is too good to be true".

On December 20, 2023, the Federal Court issued a Notice to the Parties and the Profession regarding the use of artificial intelligence in court proceedings. In line with several other provincial

The Pharmaceutical and Life Sciences Sector Task Force has released its final report addressing Canada's challenges in medication access, regulatory processes, and life sciences competitiveness. The report examines structural issues including lengthy reimbursement pathways, underperforming clinical trial environments, and erosion of domestic investment, while proposing 39 recommendation areas to strengthen Canada's health sovereignty and industrial strategy.

For a Canadian patent application to be examined, an applicant must file a request for examination with the Canadian Intellectual Property Office (CIPO). In most cases, the order in which applications are examined is based on the order that the requests for examination are received. An applicant may be able to accelerate examination of their patent application through several existing mechanisms, including advancing examination via special order, accelerating examination of applications related to green technology, and the Patent Prosecution Highway (PPH).

The Board will hold a public hearing (on a date to be determined no later than February 27, 2019) to determine whether Horizon Therapeutics Canada is selling ...

On February 15, 2017, the European Parliament voted to approve the Canada-EU Comprehensive Economic and Trade Agreement (CETA).

As we previously reported, Health Canada consulted on the framework for clinical trials, including on the new Clinical Trials Regulations and draft and updated guidance documents. Health Canada has now published a What we heard overview of the results of the consultation.

On November 22, 2024, the pan-Canadian Pharmaceutical Alliance (pCPA) released its 2023-2024 impact report.

Health Canada is not currently meeting its performance standards for the review of some generic drug submissions. On September 1, 2026, Health Canada launched a new webpage, Improving how we review generic drugs, and released three notices on proposed actions to address the backlog of generic drug submissions under review.